Cocrystal Pharma (OTCMKTS:COCP) Trading 9.7% Higher

Cocrystal Pharma Inc (OTCMKTS:COCP)’s share price traded up 9.7% during mid-day trading on Tuesday . The stock traded as high as $0.50 and last traded at $0.50, 143,916 shares traded hands during trading. An increase of 374% from the average session volume of 30,383 shares. The stock had previously closed at $0.46.

The firm’s fifty day simple moving average is $1.14 and its 200-day simple moving average is $2.00.

Cocrystal Pharma (OTCMKTS:COCP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The company had revenue of $0.49 million for the quarter.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its position in shares of Cocrystal Pharma by 15.3% during the 2nd quarter. BlackRock Inc. now owns 35,323 shares of the company’s stock worth $83,000 after buying an additional 4,685 shares during the period. Vanguard Group Inc. grew its position in shares of Cocrystal Pharma by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 360,364 shares of the company’s stock worth $847,000 after buying an additional 15,336 shares during the period. Parallel Advisors LLC acquired a new stake in shares of Cocrystal Pharma during the 3rd quarter worth approximately $99,000. Finally, Wasatch Advisors Inc. grew its position in shares of Cocrystal Pharma by 5.4% during the 2nd quarter. Wasatch Advisors Inc. now owns 1,152,731 shares of the company’s stock worth $2,709,000 after buying an additional 59,235 shares during the period.

About Cocrystal Pharma (OTCMKTS:COCP)

Cocrystal Pharma, Inc, formerly Biozone Pharmaceuticals, Inc, is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus.

Featured Article: Stock Symbols, CUSIP and Other Stock Identifiers

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.